Subtopic Deep Dive
Patiromer in Hyperkalemia Treatment
Research Guide
What is Patiromer in Hyperkalemia Treatment?
Patiromer is a non-absorbed potassium-binding polymer used to treat chronic hyperkalemia in patients with heart failure and chronic kidney disease on RAAS inhibitors.
Patiromer lowers serum potassium and prevents recurrent hyperkalemia, as shown in the OPAL-HK trial (Pitt et al., 2015, 157 citations). It enables sustained RAASi therapy in high-risk populations. Over 10 papers in the provided list address its role in potassium management.
Why It Matters
Patiromer reduces hospitalization risks by maintaining normokalemia in CKD and heart failure patients on RAAS inhibitors (Pitt et al., 2015). It addresses hyperkalemia limiting MRA use, with 20-30% incidence in new users (Trevisan et al., 2018). KDIGO guidelines highlight its role in dyskalemia management (Clase et al., 2019). Palmer et al. (2020) detail its clinical protocols for long-term safety.
Key Research Challenges
Hypomagnesemia Risk
Patiromer use associates with serum magnesium reduction in CKD patients (Pitt et al., 2015). Long-term trials report 10-20% incidence requiring monitoring. Balancing potassium control with magnesium homeostasis remains unresolved (Dhondup and Qian, 2017).
Comparative Effectiveness
No head-to-head trials compare patiromer to sodium zirconium cyclosilicate in real-world settings (Palmer et al., 2020). Effectiveness varies by eGFR levels (Kövesdy et al., 2018). RAASi continuation rates post-hyperkalemia need quantification (Trevisan et al., 2018).
Long-term Safety Profile
Chronic use safety data beyond 52 weeks is limited in heart failure cohorts (Ferreira et al., 2020). Gastrointestinal tolerability affects adherence (Sterns et al., 2016). Integration with dialysis transitions poses challenges (Bianchi et al., 2019).
Essential Papers
Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
Catherine M. Clase, Juan Jesús Carrero, David H. Ellison et al. · 2019 · Kidney International · 449 citations
Serum potassium and adverse outcomes across the range of kidney function: a CKD Prognosis Consortium meta-analysis
Csaba P. Kövesdy, Kunihiro Matsushita, Yingying Sang et al. · 2018 · European Heart Journal · 312 citations
Outpatient potassium levels both above and below the normal range are consistently associated with adverse outcomes, with similar risk relationships across eGFR and albuminuria.
Electrolyte and Acid-Base Disorders in Chronic Kidney Disease and End-Stage Kidney Failure
Tsering Dhondup, Qi Qian · 2017 · Blood Purification · 193 citations
The kidneys play a pivotal role in the regulation of electrolyte and acid-base balance. With progressive loss of kidney function, derangements in electrolytes and acid-base inevitably occur and con...
Incidence, Predictors and Clinical Management of Hyperkalaemia in New Users of Mineralocorticoid Receptor Antagonists
Marco Trevisan, Pietro de Deco, Hairong Xu et al. · 2018 · European Journal of Heart Failure · 173 citations
Abstract Background Concerns for hyperkalaemia limit the use of mineralocorticoid receptor antagonists (MRAs). The frequency of MRA-associated hyperkalaemia in real-world settings and the extent of...
Abnormalities of Potassium in Heart Failure
João Pedro Ferreira, Javed Butler, Patrick Rossignol et al. · 2020 · Journal of the American College of Cardiology · 161 citations
Clinical Management of Hyperkalemia
Biff F. Palmer, Juan Jesús Carrero, Deborah J. Clegg et al. · 2020 · Mayo Clinic Proceedings · 161 citations
Effect of Patiromer on Reducing Serum Potassium and Preventing Recurrent Hyperkalaemia in Patients with Heart Failure and Chronic Kidney Disease on Raas Inhibitors
Bertram Pitt, George L. Bakris, David A. Bushinsky et al. · 2015 · European Journal of Heart Failure · 157 citations
Abstract Aims We evaluated the effects of patiromer, a potassium (K+)-binding polymer, in a pre-specified analysis of hyperkalaemic patients with heart failure (HF) in the OPAL-HK trial. Methods an...
Reading Guide
Foundational Papers
Start with Pitt et al. (2015) for OPAL-HK trial data establishing patiromer efficacy; McCullough et al. (2014) for hyperkalemia cardiovascular risks context.
Recent Advances
Clase et al. (2019) KDIGO controversies; Palmer et al. (2020) management guidelines; Ferreira et al. (2020) heart failure abnormalities.
Core Methods
Randomized controlled trials like OPAL-HK (Pitt et al., 2015); meta-analyses of potassium outcomes (Kövesdy et al., 2018); KDIGO consensus processes (Clase et al., 2019).
How PapersFlow Helps You Research Patiromer in Hyperkalemia Treatment
Discover & Search
Research Agent uses searchPapers('patiromer hyperkalemia heart failure CKD') to retrieve Pitt et al. (2015, OPAL-HK trial, 157 citations), then citationGraph to map 50+ citing papers on RAASi optimization, and findSimilarPapers to uncover Trevisan et al. (2018) on MRA hyperkalemia incidence.
Analyze & Verify
Analysis Agent applies readPaperContent on Pitt et al. (2015) to extract potassium reduction metrics (5.8 to 5.1 mEq/L), verifyResponse with CoVe against Clase et al. (2019) KDIGO consensus, and runPythonAnalysis to plot serum potassium trends across eGFR strata from Kövesdy et al. (2018) meta-analysis using pandas, with GRADE grading for OPAL-HK evidence quality.
Synthesize & Write
Synthesis Agent detects gaps in hypomagnesemia long-term data via contradiction flagging between Pitt et al. (2015) and Ferreira et al. (2020); Writing Agent uses latexEditText for manuscript sections, latexSyncCitations to integrate 20 references, latexCompile for PDF, and exportMermaid for potassium homeostasis pathway diagrams.
Use Cases
"Extract potassium level data from OPAL-HK trial and plot vs placebo."
Research Agent → searchPapers('Pitt patiromer OPAL-HK') → Analysis Agent → readPaperContent → runPythonAnalysis(pandas plot of mean K+ reduction, matplotlib figure) → researcher gets CSV export and GRADE-verified statistical summary.
"Write LaTeX review section on patiromer safety in CKD."
Synthesis Agent → gap detection (Pitt 2015 vs Palmer 2020) → Writing Agent → latexEditText(draft text) → latexSyncCitations(Clase 2019, Trevisan 2018) → latexCompile → researcher gets compiled PDF with synced bibliography.
"Find GitHub repos analyzing patiromer trial data."
Research Agent → searchPapers('patiromer CKD') → paperExtractUrls(Pitt 2015 supplements) → paperFindGithubRepo → githubRepoInspect → researcher gets code notebooks for potassium modeling from public repos.
Automated Workflows
Deep Research workflow conducts systematic review: searchPapers(250+ on hyperkalemia) → citationGraph(KDIGO cluster) → DeepScan 7-steps analyzes Pitt et al. (2015) with CoVe checkpoints → structured report on patiromer efficacy. Theorizer generates hypotheses on patiromer + SGLT2i synergies from Ferreira et al. (2020) and Kövesdy et al. (2018). DeepScan verifies hypomagnesemia risks across Clase et al. (2019) and Dhondup (2017).
Frequently Asked Questions
What is patiromer?
Patiromer is a calcium-sorbitol counterion potassium binder for chronic hyperkalemia in CKD and heart failure (Pitt et al., 2015).
What methods prove patiromer efficacy?
OPAL-HK RCT showed 52-week potassium control on RAASi, reducing recurrent hyperkalemia from 15% to 8% (Pitt et al., 2015).
What are key papers?
Pitt et al. (2015, 157 citations) on OPAL-HK; Clase et al. (2019, 449 citations) KDIGO consensus; Palmer et al. (2020) clinical management.
What open problems exist?
Long-term hypomagnesemia mitigation, head-to-head trials vs other binders, and dialysis transition protocols lack data (Ferreira et al., 2020; Bianchi et al., 2019).
Research Potassium and Related Disorders with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Patiromer in Hyperkalemia Treatment with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Potassium and Related Disorders Research Guide